Aura Biosciences, Inc. (NASDAQ:AURA) has received agreement from the U.S. Food and Drug Administration (FDA) for the design and planned analysis of its global Phase 3 clinical trial of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma. The company also presented positive Phase 2 safety and efficacy data of bel-sar with 90% of patients at twelve months of follow-up showing tumor control and visual acuity preservation. Preliminary data from a Phase 1 trial in bladder cancer showed a clinical complete response in the first patient using a single dose of bel-sar with light activation.